Loading company…
Shanghai Yizhong develops new dosage forms of anti-tumor drugs, including paclitaxel polymer micelles.
Founded in 2009 and based in Shanghai, China, Shanghai Yizhong Pharmaceutical develops new dosage forms of anti-tumor drugs and related products. Its main product is paclitaxel polymer micelles for injection, used to treat malignant tumors. The company was listed on the Shanghai Stock Exchange in 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in